Ambrx Looks Across Pacific For A Secure Future
This article was originally published in PharmAsia News
Executive Summary
Rather than reviving its own IPO plans, U.S. bioventure Ambrx has turned to a consortium of Chinese investors to secure its future via an acquisition deal that will provide funding for its pipeline and facilitate access to a large market and new partners.
You may also be interested in...
Finance Watch: Billions In And Billions Out In Venture Capital Fundraising
Private Company Edition: The flood of venture capital into health care and life science firms continues with Perceptive closing a $1.1bn credit fund and Sanofi investing $50m in Jeito Capital. Also, Ambrx closed a $200m crossover round as biopharma remains on track for a record funding year.
Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
FDA Warning Letter Could Impact Zhejiang Medicine’s US Foray
Zhejiang Medicine has become the latest major Chinese API firm to be hit with a US FDA warning letter amid stepped up oversight of production facilities in China by the US regulator, which has led to a string of similar actions this year alone. But efforts are now being made both by Chinese manufacturers and by authorities in the two countries to ensure adherence to international standards.